Skills

People expertise

  • Adrian Harris
    Phase I/II trials PK PD endpoints Angiogenesis, hypoxia, molecular markers, breast cancer, melanoma
  • Mark Middleton
    Phase I/II trials PK PD endpoints, phase III Melanoma, upper GI, DNA repair
  • Denis Talbot
    Phase I/II trials PK PD endpoints phase III, lung and breast, DNA repair
  • Ian Hickson
    DNA damage and repair PD endpoints
  • Peter McHugh
    DNA damage and repair PD endpoints
  • Vincenzo Cerundolo
    Tumour immunology and immunotherapy
  • Rachel Midgley
    Tumour immunology and immunotherapy, gene therapy, lower GI oncology
  • Rachel Gatter
    Molecular pathology, biopsy analysis, antibody generation, TMAs
  • Francesco Pezzella
    Molecular pathology, biopsy analysis, antibody generation, TMAs
  • Ruth Muschel
    Tumour vasculature, molecular pathology and molecular correlates in radiation trials
  • Gillies McKenna
    Radiation combination therapy, phase I/II, signalling pathways, DNA repair
  • Katherine Vallis
    Radiation combination therapy, phase I/II, targeted isotope therapy, growth factor receptors
  • Andrew Protheroe
    Phase I/II trials PK PD endpoints, phase III Urological cancer, immunotherapy
  • David Kerr
    Phase I/II trials PK PD endpoints, phase III Lower GI cancer
  • Len Seymour
    Gene therapy and vascular targeting PD and PK analysis in gene and immunogene therapy trials, production of viral vectors to GLP
  • James Wainscoat
    Analysis of nucleic acids in biological samples, genetic and molecular analyses from formalin sections
  • Suzanne Watt
    CGMP for production of dendritic cells , analysis of cell populations by FACS, support of immunological and anti- angiogenesis trials
  • Janusz Jankowski
    Clinical studies of prevention in Phase I/II/III, molecular endpoints and analyses
  • Richard Callaghan
    Expertise in drug resistance and combined preclinical approaches for phase I design
  • Douglas Altman
    Medical statistics, design and interpretation of trials, assays and predictive and prognostic studies
  • Mariolina Salio
    Culture of dendritic cells, activation pathways and assays for trials